Press Releases

bioMérieux’s Annual General Meeting postponed

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on...

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...

2019 Financial Results

€2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sale...

Financial Information

Résultats annuels au 31 décembre 2019

Chiffre d’affaires 2019 de 2 675 millions d’euros, en hausse de 10,5 % à données publiées, soit une croissance organique de 7,2 % Solide dynamique commerciale au 4e trimestre, avec une croissance orga...

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clear...